• 1. Isoflavonoids of the Leguminosae
  Nigel C. Veitch Nat. Prod. Rep. 2007 24 417
• 2. Protective effect of liquiritigenin against methylglyoxal cytotoxicity in osteoblastic MC3T3-E1 cells
  Kwang Sik Suh,Sang Youl Rhee,Young Seol Kim,Eun Mi Choi Food Funct. 2014 5 1432
• 3. 248. Chalkones. Condensation of aromatic aldehydes with resacetophenone. Part II
  D. R. Nadkarni,T. S. Wheeler J. Chem. Soc. 1938 1320
• 4. LC-ESI-MS/MS method for the enantioseparation of six flavanones
  Irena Baranowska,Judyta Hejniak,Sylwia Magiera Anal. Methods 2017 9 1018
• 5. A new method for screening aldose reductase inhibitors using ultrahigh performance liquid chromatography-tandem mass spectrometry
  Guangyue Hou,Ruixing Zhang,Zifeng Pi,Fengrui Song,Zhiqiang Liu,Shuying Liu Anal. Methods 2014 6 7681

• Solvents and Organic Chemicals Organic Compounds Phenylpropanoids and polyketides Flavonoids Flavanones
• Solvents and Organic Chemicals Organic Compounds Phenylpropanoids and polyketides Flavonoids Flavans Flavanones
• Flavonones
• Flavonoids
• Pharmaceutical and Biochemical Products Pharmaceutical Active Ingredients Standard Substances
• Solvents and Organic Chemicals Organic Compounds Aldehyde/Ketone

Liquiritigenin (CAS No. 578-86-9): A Comprehensive Overview of Its Chemical Profile and Emerging Therapeutic Applications

Liquiritigenin, chemically identified by the CAS number 578-86-9, is a naturally occurring flavonoid derivative renowned for its diverse pharmacological properties. This compound, primarily extracted from the roots of Glycyrrhiza glabra (licorice), has garnered significant attention in the field of pharmaceutical chemistry and medicinal biology due to its potent biological activities. The structural framework of Liquiritigenin features a flavonolignan core, which contributes to its remarkable antioxidant, anti-inflammatory, and anticancer effects. This introduction delves into the chemical characteristics, pharmacological mechanisms, and the latest research findings associated with Liquiritigenin, emphasizing its potential as a therapeutic agent in modern medicine.

The molecular structure of Liquiritigenin (CAS No. 578-86-9) consists of a flavone moiety linked to a glycoside unit, forming a unique flavonolignan configuration. This structural feature imparts exceptional stability and bioactivity, enabling it to interact with various cellular targets. The compound exhibits significant antioxidant properties by neutralizing reactive oxygen species (ROS) and modulating enzymatic antioxidants such as superoxide dismutase (SOD) and catalase. These mechanisms are crucial in mitigating oxidative stress, a key factor in numerous pathological conditions, including neurodegenerative diseases and cardiovascular disorders.

Recent studies have highlighted the anti-inflammatory potential of Liquiritigenin. It has been demonstrated to inhibit the expression of pro-inflammatory cytokines such as tumor necrosis factor-alpha (TNF-α), interleukin-1β (IL-1β), and interleukin-6 (IL-6). By modulating nuclear factor kappa B (NF-κB) signaling pathways, Liquiritigenin effectively reduces inflammation in various cellular models. This anti-inflammatory action makes it a promising candidate for treating chronic inflammatory diseases, such as rheumatoid arthritis and inflammatory bowel disease.

The anticancer properties of Liquiritigenin have been extensively investigated in recent years. Preclinical studies indicate that it can induce apoptosis in cancer cells through multiple mechanisms, including the activation of caspase-dependent pathways and the inhibition of survival signaling cascades like Akt/mTOR. Additionally, Liquiritigenin has shown promise in suppressing tumor growth by inhibiting angiogenesis—the formation of new blood vessels that supply nutrients to cancerous tissues. Notably, research has focused on its efficacy against various cancer types, including breast, liver, and colon cancers. The molecular interactions between Liquiritigenin and key oncogenic proteins have been elucidated, providing insights into its therapeutic potential.

The pharmacokinetic profile of Liquiritigenin is another critical aspect that influences its clinical applicability. Studies suggest that it exhibits moderate oral bioavailability due to its rapid absorption from the gastrointestinal tract. However, its metabolic stability is relatively short-lived, necessitating optimized delivery systems for enhanced therapeutic efficacy. Advances in nanotechnology have enabled the development of novel formulations such as liposomes and nanoparticles, which can improve the solubility and target specificity of Liquiritigenin. These innovations are poised to enhance its bioavailability and prolong its pharmacological effects.

The safety profile of Liquiritigenin has been evaluated through both preclinical and clinical trials. Preliminary findings indicate that it exhibits low toxicity at therapeutic doses, with minimal side effects observed in animal models. However, long-term studies are necessary to fully assess its safety profile in human populations. Clinical trials are currently underway to evaluate its efficacy in treating chronic inflammatory conditions and cancerous tumors. The results of these trials are expected to provide further evidence supporting the therapeutic potential of this compound.

The integration of computational chemistry and artificial intelligence has accelerated the discovery of novel derivatives with enhanced pharmacological properties. By leveraging machine learning algorithms, researchers have identified structural modifications that can improve the bioactivity and selectivity of Liquiritigenin. These computational approaches have not only expedited drug development but also provided valuable insights into the molecular interactions governing its biological effects. Such advancements underscore the importance of interdisciplinary collaboration between chemists, biologists, and computer scientists in unlocking the full potential of natural products like Liquiritigenin.

In conclusion, Liquiritigenin (CAS No. 578-86-9) represents a promising natural product with multifaceted therapeutic applications. Its potent antioxidant, anti-inflammatory, and anticancer properties make it an attractive candidate for developing novel pharmaceuticals. Ongoing research efforts are focused on optimizing its delivery systems, elucidating its mechanistic pathways, and conducting clinical trials to validate its clinical efficacy. As our understanding of molecular medicine continues to evolve, compounds like Liquiritigenin are poised to play a pivotal role in addressing some of the most pressing challenges in modern healthcare.

• 520-33-2(Hesperetin)
• 552-58-9(Eriodictyol)
• 487-26-3(Flavanone)
• 4250-77-5(6-Hydroxyflavanone)
• 24211-30-1(Farrerol)
• 36052-37-6(Alpinetin)
• 480-37-5(Pinostrobin)
• 480-41-1(Naringenin)
• 1090-65-9(7-Hydroxy-5-methoxy-2-phenylchroman-4-one)
• 3034-04-6(6-Methoxy-2-phenyl-2,3-dihydrochromen-4-one)